

HLAVNÍ TÉMA

ANTIKOAGULAČNÁ LIEČBA U PACIENTOV S FIBRILÁCIOU PREDSENÍ PO PREKONANÍ ISCHEMICKEJ CIEVNEJ MOZGOVEJ PRÍHODY

7. Hindsholm MF, García Rodríguez LA, Brandes A, et al. Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants. *JAMA Neurol.* 2024;81(8):805-813. doi:10.1001/jamaneurol.2024.1892.
8. Hsieh MT, Liu CH, Lin SH, et al. Recurrent Ischemic Stroke and Cardiovascular Outcomes in Patients With Atrial Fibrillation With Ischemic Stroke Despite Direct Oral Anticoagulants. *Stroke.* 2023;54(4):e145-e146.
9. Ip YMB, Lau KK, Ko H, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant. *Neurology.* 2023;101(4):e358-e369.
10. Kanuri SH, Kreutz RP. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. *J Pers Med.* 2019;9(1):7.
11. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke.* 2021;52(7).
12. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. *Eur Stroke J.* 2019;4(3):198-223.
13. Lin S, Liao Y, Tang S, Lin CC, Wang C. Changing or Retaining Direct Oral Anticoagulant After Ischemic Stroke Despite Direct Oral Anticoagulant Treatment. *J Am Heart Assoc.* 2024;13(3):e032454.
14. Merella P, Casu G, Chessa P, Atzori E, Bandino S, Deiana G. When Atrial Fibrillation Meets Cerebral Amyloid Angiopathy: Current Evidence and Strategies. *J Clin Med.* 2023;12(24):7704.
15. Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. *Res Pract Thromb Haemost.* 2020;4(4):550-561.
16. Nosál V, Petrovičová A, Škorňová I, et al. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. *Eur J Clin Pharmacol.* 2022;78(4):557-564.
17. Oldgren J, Åsberg S, Hijazi Z, et al. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. *Circulation.* 2022;146(14):1056-1066.
18. Paciaroni M, Caso V, Romoli M, et al. Anticoagulation in acute ischemic stroke patients with mechanical heart valves: To bridge or not with heparin. The ESTREM study. *Eur Stroke J.* Published online July 15, 2023.
19. Polymeris AA, Meinel TR, Oehler H, et al. Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. *J Neurol Neurosurg Psychiatry.* 2022;93(6):588-598.
20. Rao MP, Vinereanu D, Wojdyła DM, et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. *Am J Med.* 2018;131(3):269-275.e2.
21. Rossel A, Robert-Ebadi H, Combescure C, et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. *PLOS ONE.* 2019;14(3):e0213940.
22. Sarathy PP, Cruces F. 658 THE RISK OF ANTICOAGULATION IN ELDERLY FALLERS WITH ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Age Ageing.* 2022;51(Supplement_1):afac036.658.
23. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *EP Eur.* 2021;23(10):1612-1676.
24. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. *J Am Coll Cardiol.* 2016;68(11):1169-1178.
25. Tanaka K, Koga M, Lee KJ, et al. Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke. *Stroke.* 2020;51(4):1150-1157. doi:10.1161/STROKEAHA.119.027275.
26. Xu Y, Liu C, Li W, et al. Efficacy and safety of early anticoagulation after endovascular treatment in patients with atrial fibrillation. *Stroke Vasc Neurol.* 2023;8(5):405-412.

ON-LINE KURZ

Zaostřeno na syndrom Dravetové

OBSAH KURZU

- ▶ **Co víme o syndromu Dravetové u dospělých?** – prof. MUDr. Petr Marusič, Ph.D.
- ▶ **Na co ještě myslet u dětí?** – MUDr. Martin Kudr, Ph.D.
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Katalin Štěrbová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Jana Zárubová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Markéta Vlčková, Ph.D.
- ▶ **Mechanismus účinku a protizáchvatová aktivita fenfluraminu** – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D.

ODBORNÝ GARANT:

doc. MUDr. Irena Doležalová, Ph.D.

POŘADATEL:

Společnost SOLEN, s. r. o.,
ve spolupráci s I. neurologickou klinikou LF MU
a FN u sv. Anny

Registrace
ZDARMA

TERMÍN

květen 2024 až duben 2025

dostupný na
online.solen.cz



ZLATÝ
PARTNER



Inspired by patients.
Driven by science.

